Chardan Capital Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $13.00 price target on the stock.

Separately, Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Immuneering in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.80.

Immuneering Stock Up 3.4 %

NASDAQ IMRX opened at $2.11 on Wednesday. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $8.89. The business has a 50 day moving average price of $2.22 and a two-hundred day moving average price of $1.62. The stock has a market cap of $65.52 million, a PE ratio of -1.07 and a beta of -0.40.

Institutional Trading of Immuneering

A number of hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP bought a new position in Immuneering during the 2nd quarter valued at $492,000. Renaissance Technologies LLC bought a new position in shares of Immuneering during the second quarter worth about $447,000. Vanguard Group Inc. grew its stake in Immuneering by 12.1% in the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after purchasing an additional 129,851 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Immuneering in the second quarter valued at about $67,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Immuneering during the second quarter valued at approximately $44,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.